Intercept's INT-747 meets cirrhosis endpoint

Intercept Pharmaceuticals Inc. (New York, N.Y.) said INT-747 plus ursodeoxycholic acid (UDCA) met the primary endpoint of significantly reducing levels of alkaline phosphatase vs. placebo plus UDCA at...